VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
ENLV
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
ENLVEnlivex Therapeutics Ltd.
$0.57$14M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders

ENLV logoEnlivex Therapeutics Ltd.(ENLV)Earnings, Financials & Key Ratios

ENLV•NASDAQ
$0.58
0.0× P/E·Price updated Jun 25, 2026
SectorHealthcareIndustryBiotechnologySub-IndustryCell and Gene Therapy Developers
AboutEnlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.Show more
  • Revenue$0
  • EBITDA-$15M+2.2%
  • Net Income$1.24B+8329.2%
  • EPS (Diluted)25.48+3590.4%
  • ROE126.17%+325.5%

ENLV Price & Volume

Enlivex Therapeutics Ltd. (ENLV) stock price & volume — 10-year historical chart

Loading chart...

Accounting Anomalies Mask Critical Clinical Liquidity Risk

Investment Thesis • Updated 2025Q4

VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity and dilution

Key Thesis Takeaways

  • Enlivex Therapeutics faces an existential liquidity crisis as it continues to operate without commercial revenue, relying on external capital to fund its $3.0 million quarterly R&D expenditures.
  • While the 2025Q4 balance sheet reports $2.3 billion in total assets, this figure is heavily distorted by $582.5 million in goodwill and non-operating accounting adjustments that obscure a precarious $2.0 million cash position.
  • Investors should remain cautious, as the company's inability to generate positive free cash flow, evidenced by a $2.9 million burn in 2025Q4, necessitates ongoing dilution to sustain its clinical-stage pipeline.

Verdict Logic

the company's $2.0 million cash balance against a $2.9 million quarterly cash burn suggests an imminent liquidity risk that outweighs the potential upside of its clinical-stage therapeutic candidates.

ENLV Growth Metrics

Enlivex Therapeutics Ltd. (ENLV) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-
5 Years-
3 Years-
TTM-

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM8329.17%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM3540.54%

Return on Capital

10 Years-60.85%
5 Years-37.35%
3 Years-40.72%
Last Year-1.28%

ENLV Recent Earnings

Enlivex Therapeutics Ltd. (ENLV) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 8/12 qtrs (67%)
Q4 2025Latest
Nov 14, 2025
Metric
Actual
Est
EPS
$0.09+25.0%
$0.12
Rev
—
—
Q3 2025
Aug 29, 2025
Metric
Actual
Est
EPS
$0.08+50.0%
$0.16
Rev
—
—
Q2 2025
May 30, 2025
Metric
Actual
Est
EPS
$0.15+6.3%
$0.16
Rev
—
—
Q1 2025
Feb 26, 2025
Metric
Actual
Est
EPS
$0.24-47.8%
$0.16
Rev
—
—
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q4 2025LatestNov 14, 2025
$0.09vs $0.12+25.0%
—
Q3 2025Aug 29, 2025
$0.08vs $0.16+50.0%
—
Q2 2025May 30, 2025
$0.15vs $0.16+6.3%
—
Q1 2025Feb 26, 2025
$0.24vs $0.16-47.8%
—
Based on last 12 quarters of dataView full earnings history →

Latest ENLV News

Recent stock market news and headlines for Enlivex Therapeutics Ltd. (ENLV)

GlobeNewsWire·5 days ago
Enlivex Treasury Portfolio Update: Listing of the RAIN Token on Gate, One of the World's Largest Cryptocurrency Exchanges by Spot Trading Volume

Nes-Ziona, Israel, June 24, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, “ Enlivex ” or the “ Company ” ), a quality longevity company powered by a prediction markets treasury, today announced that its primary treasury asset, the RAIN token, is expected to be listed on the Gate cryptocurrency exchange, effective June 24, 2026 at 10:00 AM UTC. The listing represents a continued expansion of RAIN ' s exchange infrastructure, increasing its accessibility, global reach, and token liquidity. According to Gate, it is one of the world ' s pioneering cryptocurrency exchanges, established in 2013 . Gate is currently serving over 54 million users globally , consistently rank ed among the top three digital asset exchanges worldwide by trading volume and liquidity, and holds the second-largest 24-hour spot trading volume globally. Gate supports spot trading, futures trading, margin trading, and wealth management products for over 4,600 cryptocurrencies.

GlobeNewsWire·Jun 22, 2026
Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.14 Billion

Nes-Ziona, Israel, June 22, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, "Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today provided an update on its RAIN token holdings. As of June 20, 2026, the Company held 79,568,550,005 RAIN tokens with a total value of approximately $1.14 billion1.

Peers Comparison

Key metrics vs top competitors for Enlivex Therapeutics Ltd. (ENLV)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
ENLV logoENLVEnlivex Therapeutics Ltd.Current
$0.58$14.11M0.02——126.17%—
FATE logoFATEFate Therapeutics, Inc.
$1.87$217.97M-1.63-51.24%-2056.79%-58.89%—
MCRB logoMCRBSeres Therapeutics, Inc.
$6.85$65.93M10.70—-4088.84%-127.3%—
ADMA logoADMAADMA Biologics, Inc.
$8.72$2.02B14.5319.63%32.43%38.97%—
IMVT logoIMVTImmunovant, Inc.
$38.24$7.85B-13.81——-68.16%—
ARQT logoARQTArcutis Biotherapeutics, Inc.
$26.69$3.34B-205.3191.34%-0.57%-1.41%—

Compare ENLV vs Peers

Enlivex Therapeutics Ltd. (ENLV) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs FATE

Most directly comparable listed peer for ENLV.

Scale Benchmark

vs MEDP

Larger-name benchmark to compare ENLV against a more recognizable public peer.

Peer Set

Compare Top 5

vs FATE, MCRB, ADMA, IMVT

Get notified when ENLV posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

ENLV Frequently Asked Questions

Enlivex Therapeutics Ltd. (ENLV) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
Is ENLV profitable?

Yes, Enlivex Therapeutics Ltd. (ENLV) is profitable, generating $1.24B in net income for fiscal year 2025.

Dividend & Returns
What is ENLV's return on equity?

Enlivex Therapeutics Ltd. (ENLV) has a return on equity (ROE) of 126.2%. This is excellent, indicating efficient use of shareholder capital.

What is Enlivex Therapeutics Ltd.'s free cash flow?

Enlivex Therapeutics Ltd. (ENLV) had negative free cash flow of $11.1M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in ENLV back in 2012?

Total return calculator · dividends reinvested · 14+ years of data

See returns →